Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy [0.03%]
克霉唑在癌症治疗中的新用途及疗效研究
Shubham C Karpe,Manjula Kiran,Sukhen Majhi et al.
Shubham C Karpe et al.
Cancer, ranging from early stages to metastatic spread, is one of the leading causes of death globally. Current treatment options, including chemotherapy, radiotherapy, and targeted drugs, have limitations, such as significant side effects,...
Emerging risk factors and the role of gut microbiota in immunomodulation and therapeutic implications in colorectal cancer [0.03%]
新兴风险因素及肠道菌群在免疫调节和治疗中的作用及其对结直肠癌的影响
Sonakshi Modeel,Sneha Siwach,Padma Dolkar et al.
Sonakshi Modeel et al.
The pathophysiology of many ailments, including neurological, gastrointestinal, and metabolic problems, is well known to be influenced by intestinal dysbiosis. Clinical research has provided evidence suggesting a strong correlation between ...
Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies [0.03%]
肝癌经动脉化疗栓塞治疗新进展：与系统性治疗联合及新兴疗法的探索
Henry Sutanto,Galih Januar Adytia,Elisa Elisa et al.
Henry Sutanto et al.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, posing considerable challenges due to its complex progression and limited curative options. Transarterial chemoembolization (TACE) is a cornerston...
Oral reovirus therapy modulates gut microbiota to enhance antitumor immunity in colon cancer [0.03%]
口服再病毒治疗可调节肠道微生物群以增强结直肠癌的抗肿瘤免疫反应
S Balachandran,S Muthamizh,Elangovan Dilipan
S Balachandran
Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study [0.03%]
放疗联合一线抗程序性细胞死亡蛋白1(PD-1)免疫治疗和化疗治疗晚期非小细胞肺癌患者：一项两中心回顾性研究
Yu Huang,Peng Ding,Ruiguang Zhang et al.
Yu Huang et al.
Background: Several studies have demonstrated the synergistic effects of immunotherapy and radiotherapy for both local and abscopal tumor control. However, data regarding the use of first-line immunochemotherapy (ICT) com...
Emerging strategies in neoadjuvant therapy for non-small cell lung cancer: Progress and future directions [0.03%]
非小细胞肺癌新辅助治疗新兴策略：进展与未来方向
Ying Li,Yue Wang,Junfeng Zhao et al.
Ying Li et al.
Efficacy of local consolidative radiotherapy with first-line chemoimmunotherapy in synchronous oligometastatic esophageal squamous cell carcinoma [0.03%]
一线化疗免疫治疗联合局部巩固放疗同步寡转移食管鳞癌疗效探索
Xinyi Wang,Haixia Shen,Miao Wang et al.
Xinyi Wang et al.
Background: Synchronous oligometastatic esophageal squamous cell carcinoma (SOESCC), characterized by a limited number of metastases at diagnosis, represents a significant subset of esophageal squamous cell carcinoma. How...
Bacteriophage-based therapies in oral cancer: A new frontier in oncology [0.03%]
噬菌体在口腔癌症治疗中的应用：肿瘤学的新前沿
Vishnu Priya Panneerselvam,Leela Kagithakara Vajravelu,Rahul Harikumar Lathakumari et al.
Vishnu Priya Panneerselvam et al.
The human oral cavity harbors a diverse and dynamic microbial ecosystem, including bacteriophages (phages), which play a critical role in shaping the microbial community structure. Bacteriophages, viruses that specifically target and infect...
Relative treatment effects of first-line chemotherapy and immunotherapy for hepatocellular carcinoma: A systematic review and meta-analysis [0.03%]
一线化疗和免疫治疗肝细胞癌的相对疗效：系统评价和 Meta 分析
Janak Bahirwani,Suruchi Jai Kumar Ahuja,Madhav Changela et al.
Janak Bahirwani et al.
Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the fourth most common cause of cancer-related mortality worldwide. Despite advances in immunotherapies and targeted treatments fo...
Repurposing antibiotics: A dual-action approach against bacteria-induced cancer [0.03%]
抗生素再利用：对抗细菌诱导癌症的双重作用方法
Aditya Upadhyay,Hem Chandra Jha,Dharm Pal et al.
Aditya Upadhyay et al.
Antibiotic resistance and the growing burden of bacteria-induced cancers highlight the urgent need for innovative therapeutic approaches. Drug repurposing, leveraging pre-approved antibiotics for novel applications, is a promising strategy ...